Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)

Inhibikase Therapeutics (IKT) has 3 years of Capital Leases data on record, last reported at $58330.0 in Q1 2024.

  • On a quarterly basis, Capital Leases fell 67.25% to $58330.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $58330.0, a 67.25% decrease, with the full-year FY2023 number at $90124.0, down 56.13% from a year prior.
  • Capital Leases reached $58330.0 in Q1 2024 per IKT's latest filing, down from $90124.0 in the prior quarter.
  • Over the last five years, Capital Leases for IKT hit a ceiling of $232020.0 in Q3 2022 and a floor of $58330.0 in Q1 2024.
  • A 3-year average of $147859.9 and a median of $149971.0 in 2023 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: crashed 47.84% in 2023, then plummeted 67.25% in 2024.
  • Tracing IKT's Capital Leases over 3 years: stood at $205451.0 in 2022, then tumbled by 56.13% to $90124.0 in 2023, then plummeted by 35.28% to $58330.0 in 2024.
  • Business Quant data shows Capital Leases for IKT at $58330.0 in Q1 2024, $90124.0 in Q4 2023, and $121013.0 in Q3 2023.